Weed (BUDZ) Total Non-Current Liabilities (2023 - 2026)
Weed (BUDZ) posted quarterly Total Non-Current Liabilities of $1.3 million for Q1 2026, up 48.77% year-over-year from $885564.0 in Q1 2025, and up 8.66% quarter-over-quarter from $1.2 million in Q4 2025.
Weed (BUDZ) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Weed's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 48.77% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 48.77% YoY), while the FY2025 annual figure was $1.2 million, up 31.28% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.3 million, up from $1.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.3 million in Q1 2026, with the low at $559979.0 in Q2 2024.
- The 4-year median for Total Non-Current Liabilities is $904568.0 (2024), against an average of $869833.2.
- Peak annual rise in Total Non-Current Liabilities reached 71.62% in 2025, while the deepest fall reached 31.28% in 2025.
- Weed's Total Non-Current Liabilities stood at $612953.0 in 2023, then jumped by 50.68% to $923572.0 in 2024, then soared by 31.28% to $1.2 million in 2025, then climbed by 8.66% to $1.3 million in 2026.
- Business Quant data shows BUDZ's Total Non-Current Liabilities at $1.3 million in Q1 2026, $1.2 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Weed | 3.13 Mn | 3.13 Mn | - | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.32 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 961,033.00 |
| Mar 31, 2025 | 885,564.00 |
| Dec 31, 2024 | 923,572.00 |
| Sep 30, 2024 | 649,245.00 |
| Jun 30, 2024 | 559,979.00 |
| Mar 31, 2024 | 560,533.00 |
| Dec 31, 2023 | 612,953.00 |